Vericel Corporation
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $2.05B |
| Revenue | $292M |
| Net Income | $21M |
| Total Assets | $486M |
| Net Assets | $356M |
| Employees | 398 |
| Value | |
| P/E | 95.42x |
| P/B | 5.75x |
| PEG | 1.61x |
| P/S | 7.01x |
| EV/EBITDA | 60.98x |
| FCF Yield | 2.82% |
| Profitability | |
| ROE | 6.02% |
| ROA | 4.42% |
| Op. Margin | 5.40% |
| Revenue Growth | 30.09% |
| Earnings Growth | 59.41% |
| Financial Health | |
| Debt Ratio | 36.32% |
| Total Debt | $94M |
| FCF | $58M |
| Cash | $109M |
| Current Ratio | 5.18x |
| Net Debt/EBITDA | -0.45x |
| Performance | |
| 1Y Return | -4.02% |
| 1M Return | 16.27% |
| From 52W High | -7.96% |
| 1Y MDD | -37.78% |
| Trading | |
| Volume | 1,441,225 shares |
| Trading Value | $57M |
| Per Share | |
| EPS | $0.33 |
| BPS | $7.01 |
Company Info
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.